Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (retinal ganglion cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 58 Parkinson's papers of 1,844 | 0.46 |
| pathways Reactome | 40 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 9973
Sealed predictions
- FGF8 in dopamine neurons, braak+0.23 (p 0.560) → -0.61 (p 0.078)receipt 9980
Swarm cases
receipt 9980: FGF8 in dopamine neurons, braak
- power
- full sample -0.32 (p 0.198, n 18), 95% CI -0.68 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.214, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range -0.46 to -0.23, sign flips 0; without severely affected donors -0.32 (p 0.198, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FGF8 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts